Tech Company Financing Transactions
Differentiated Therapeutics Funding Round
Curie.bio participated in a $5 million Seed venture round for Differentiated Therapeutics. The funding round closed on 8/1/2022.
Transaction Overview
Company Name
Announced On
8/1/2022
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of novel disease-modifying targeted protein degraders against high value precision oncology targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Differentiated Therapeutics (dx/tx) has built the first end-to-end discovery engine for Targeted Protein Degradation (TPD) which drives the discovery and optimization of novel protein degraders designed to eliminate the genetically defined drivers of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bryce Allen
Chief Operating Officer
Diala Ezzeddine
Co-Founder
Isaac Kohane
Browse more venture capital transactions:
Prev: 8/1/2022: OneOf venture capital transaction
Next: 8/2/2022: Eleven Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs